Cipla’s FDA-compliant facilities and its investments in US-based units place it in a strong position to weather potential ...

The Biosecurity Act, which prohibits US pharma companies from doing business with certain countries that are considered adversaries, presents a unique opportunity for Indian pharma companies, Cipla ...

Cipla , India's third-largest generic drugmaker by sales, reported a 15.2% rise in second-quarter profit that beat estimates, ...

Cipla Ltd, a major player in the Indian pharmaceutical sector, currently trades at ₹1,418. This price reflects a decrease of ...

Shivam Puri, CEO, Cipla Health, discusses the brand proposition of Prolyte ORS, shares strategy that helped brand achieve Rs ...

Join us on the Cipla Stock Liveblog, your hub for real-time updates and comprehensive analysis on a prominent stock. Stay in ...

Join us on the Cipla Stock Liveblog, your hub for real-time updates and comprehensive analysis on a prominent stock. Stay in ...

Shares of pharmaceutical giant Cipla dipped 5 per cent at Rs 1,403 per share on the NSE in Wednesday's intraday deals: Cipla ...

Cipla Ltd reported a 15.2% year-on-year increase in consolidated net profit to ₹1,303.53 crore for Q2FY25, with revenue at ₹7 ...

Total research and development spend reached Rs 385 crore, equivalent to 5.5 per cent of sales, a 2 per cent increase Y-o-Y.

Drugmaker Cipla expects to put the “slow seasonal growth” of its ‘One India’ business in the last quarter behind it, even as ...

Cipla share price: Cipla Ltd shares fell the most in terms of percentage among all the 50 companies in the NSE Nifty today on ...